Vanderbilt-Ingram Cancer Center

Site:	Vanderbilt-Ingram Cancer Center	Go to their website
Address:	2220 Pierce Ave. 691 Preston Building
City:	Nashville
State:	TN
Zip:	37232
Country:	USA

12 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
1	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	Terminated	Closed	Trametinib + Palbociclib	NCT02065063
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Active	Rogaratinib	NCT04595747
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Active, not recruiting	LOXO-101	NCT02576431
1	Phase 1 Study of Continuous OSI-906 Dosing	Ongoing, but not recruiting	Closed	Linsitinib (OSI-906)	NCT00514007
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	Not yet activated	INBRX-109 + Temozolomide	NCT03715933
1	Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors	Terminated	Closed	Imatinib + Sunitinib	NCT00573404
2	An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment	Completed	Closed	BIIB021 (CNF2024)	NCT00618319
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
2	AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors	Ongoing, but not recruiting	Closed	AMG 479 + AMG 655	NCT00819169